However, there are still limited clinically applicable and validated predictive biomarkers to identify HCC patients who could benefit from systemic therapy and, apart from AFP and ramucirumab, no other biomarker has been prospectively validated as a patient selection method. The gene discussed is AFP; the disease is hepatocellular carcinoma.